Revolution Medicines (RVMD) Other Gross PP&E Adjustments (2019 - 2026)
Revolution Medicines' quarterly Other Gross PP&E Adjustments came in at -$75.7 million in Q1 2026, down 11.79% year-on-year from -$85.8 million in Q1 2025, and up 1.13% quarter-over-quarter from -$76.5 million in Q4 2025.
Revolution Medicines has reported Other Gross PP&E Adjustments for 8 years, with the latest figure at -$75.7 million in Q1 2026.
- For the quarter ending Q1 2026, Other Gross PP&E Adjustments fell 11.79% year-over-year to -$75.7 million; the trailing twelve-month figure through Mar 2026 stood at -$75.7 million (down 11.79% YoY), and the FY2025 full-year result was -$76.5 million, up 16.5% from the prior year.
- Other Gross PP&E Adjustments for Q1 2026 stood at -$75.7 million, up from -$76.5 million in the prior quarter.
- The five-year high for Other Gross PP&E Adjustments was $8.4 million in Q1 2023, with the low at -$91.6 million in Q4 2024.
- Average Other Gross PP&E Adjustments over 5 years is -$43.3 million, with a median of -$35.0 million recorded in 2022.
- Year-over-year, Other Gross PP&E Adjustments jumped 124.02% in 2023 and slumped 524.42% in 2024.
- Tracing RVMD's Other Gross PP&E Adjustments over 5 years: stood at -$29.0 million in 2022, then plunged by 60.26% to -$46.5 million in 2023, then sank by 97.23% to -$91.6 million in 2024, then increased by 16.5% to -$76.5 million in 2025, then rose by 1.13% to -$75.7 million in 2026.
- The last three Other Gross PP&E Adjustments figures came in at -$75.7 million (Q1 2026), -$76.5 million (Q4 2025), and -$76.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -75.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -75.65 Mn |
| Mar 31, 2026 | -75.65 Mn |
| Dec 31, 2025 | -76.51 Mn |
| Dec 31, 2025 | -76.51 Mn |
| Sep 30, 2025 | -76.87 Mn |
| Sep 30, 2025 | -76.87 Mn |
| Jun 30, 2025 | -58.84 Mn |
| Jun 30, 2025 | -58.84 Mn |
| Mar 31, 2025 | -67.67 Mn |
| Mar 31, 2025 | -67.67 Mn |
| Dec 31, 2024 | -91.64 Mn |
| Dec 31, 2024 | -91.64 Mn |
| Sep 30, 2024 | -30.31 Mn |
| Sep 30, 2024 | -30.31 Mn |
| Jun 30, 2024 | -32.17 Mn |
| Jun 30, 2024 | -32.17 Mn |
| Mar 31, 2024 | -35.67 Mn |
| Mar 31, 2024 | -35.67 Mn |
| Dec 31, 2023 | -46.46 Mn |
| Dec 31, 2023 | -46.46 Mn |
| Sep 30, 2023 | -16.62 Mn |
| Sep 30, 2023 | -16.62 Mn |
| Jun 30, 2023 | -18.10 Mn |
| Jun 30, 2023 | -18.10 Mn |
| Mar 31, 2023 | 8.40 Mn |
| Mar 31, 2023 | 8.40 Mn |
| Dec 31, 2022 | -28.99 Mn |
| Dec 31, 2022 | -28.99 Mn |
| Sep 30, 2022 | -25.08 Mn |
| Sep 30, 2022 | -25.08 Mn |
| Jun 30, 2022 | -29.57 Mn |
| Jun 30, 2022 | -29.57 Mn |
| Mar 31, 2022 | -34.99 Mn |
| Mar 31, 2022 | -34.99 Mn |
| Dec 31, 2021 | -41.17 Mn |
| Dec 31, 2021 | -41.17 Mn |
| Sep 30, 2021 | -6.10 Mn |
| Sep 30, 2021 | -6.10 Mn |
| Jun 30, 2021 | -6.21 Mn |
| Jun 30, 2021 | -6.21 Mn |
| Mar 31, 2021 | -8.27 Mn |
| Mar 31, 2021 | -8.27 Mn |
| Dec 31, 2020 | -11.70 Mn |
| Dec 31, 2020 | -11.70 Mn |
| Sep 30, 2020 | -14.28 Mn |
| Sep 30, 2020 | -14.28 Mn |
| Jun 30, 2020 | -15.52 Mn |
| Jun 30, 2020 | -15.52 Mn |
| Mar 31, 2020 | 2.88 Mn |
| Mar 31, 2020 | 2.88 Mn |
| Dec 31, 2019 | 11.10 Mn |
| Dec 31, 2019 | 11.10 Mn |